×
About 18,580 results

ALLMedicine™ Lymphomas Center

Research & Reviews  6,102 results

Paediatric Strategy Forum for medicinal product development of chimeric antigen recepto...
https://doi.org/10.1016/j.ejca.2021.10.016
European Journal of Cancer (Oxford, England : 1990); Pearson AD, Rossig C et. al.

Nov 30th, 2021 - The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell pr...

STAT6 and phosphorylated STAT6 are differentially expressed in lymphomas.
https://doi.org/10.1016/j.prp.2021.153697
Pathology, Research and Practice; Karpathiou G, Ferrand E et. al.

Nov 29th, 2021 - The STAT6 pathway is implicated in the pathogenesis of various lymphomas; however, its immunohistochemical expression has not been fully investigated. Thus, the aim of this study was to investigate the immunohistochemical expression of the two for...

Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated wi...
https://doi.org/10.3174/ajnr.A7351
AJNR. American Journal of Neuroradiology; Jeong SY, Park JE et. al.

Nov 27th, 2021 - The microenvironment of lymphomas is known to be highly variable and closely associated with treatment resistance and survival. We tried to develop a physiologic MR imaging-based spatial habitat analysis to identify regions associated with treatme...

An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619653
International Journal of Hematology; Nishikori M, Masaki Y et. al.

Nov 27th, 2021 - Thiotepa, an antineoplastic ethylenimine alkylating agent that can penetrate the central nervous system, was recently approved in Japan as high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (HSCT) for patients with ...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Nov 25th, 2021 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

see more →

Guidelines  23 results

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and...
https://doi.org/10.1016/j.annonc.2019.10.010
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.

Jan 9th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Primary extranodal lymphoma of the glands. Literature review and options for best pract...
https://doi.org/10.1016/j.critrevonc.2019.01.005
Critical Reviews in Oncology/hematology; Belkacemi Y, Sio TT et. al.

Mar 2nd, 2019 - Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic opti...

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for ...
https://doi.org/10.1111/bjd.17240
The British Journal of Dermatology; Gilson D, Whittaker SJ et. al.

Dec 19th, 2018 - British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.|2018|Gilson D,Whittaker SJ,Child FJ,Scarisbrick JJ,Illidge TM,|methods,standards,methods,standards,therapy,t...

see more →

Drugs  257 results see all →

Clinicaltrials.gov  285 results

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04599634

Nov 25th, 2021 - Background: Indolent B-cell malignancies are associated with frequent disease relapse Standard frontline therapy includes a monoclonal anti-CD20 antibody with or without chemotherapy; novel targeted therapies have changed the treatment landscape a...

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02211755

Nov 25th, 2021 - BACKGROUND: The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models, justifying the clinical evaluation of this combinatio...

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participant...
https://clinicaltrials.gov/ct2/show/NCT03467373

Nov 25th, 2021 - This is a phase 1B, multi-center, dose-finding study of glofitamab administered in combination with obinutuzumab (Gazyva; [G]), rituximab (R) and standard doses of CHOP (G/R-CHOP or R-CHOP) in participants with r/r NHL and untreated diffuse large ...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Nov 25th, 2021 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
https://clinicaltrials.gov/ct2/show/NCT04195555

Nov 25th, 2021 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with AG-120 (ivosidenib) with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas...

see more →

News  757 results

Fast Five Quiz: Management of Mantle Cell Lymphoma
https://reference.medscape.com/viewarticle/960654

Nov 17th, 2021 - Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas. As with many other B-cell malignancies, MCL comprises a wide variety of biological and clinical variants. Consequently, its diagnosis can be challenging. The disease cou...

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium
https://www.onclive.com/view/btk-inhibitors-pi3k-inhibitors-and-car-t-cell-therapy-shake-up-hematologic-malignancies-armamentarium

Nov 15th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...

PD-L1/4-1BB–Directed Bispecific Antibody ATG-101 Shows Preclinical Efficacy Without Hepatotoxicity
https://www.onclive.com/view/pd-l1-4-1bb-directed-bispecific-antibody-atg-101-shows-preclinical-efficacy-without-hepatotoxicity

Nov 12th, 2021 - ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys, according to preclinical findings from a study presented in ...

Vaccinated Blood Cancer Patients Still at Risk for Severe COVID-19
https://www.medpagetoday.com/hematologyoncology/hematology/95535

Nov 8th, 2021 - Patients with hematologic malignancies who had breakthrough COVID-19 infections still had high risk for severe or critical disease, according to a registry-based study. Out of 113 reported cases of SARS-CoV-2 infection post-vaccination in people w...

Fast Five Quiz: Test Your Knowledge of Mantle Cell Lymphoma
https://www.medscape.com/viewarticle/879288

Nov 8th, 2021 - Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. MCL was not recognized by previous lymphoma classif...

see more →

Patient Education  8 results see all →